An Extension Study Evaluating the Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury (TBI) With Persistent Cognitive Deficits

NCT00219245 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

157

Enrollment

INDUSTRY

Sponsor class

Conditions

Traumatic Brain Injury With Persistent Cognitive Deficits

Interventions

DRUG: Rivastigmine

Sponsor

Novartis